Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupComplicationsDiseaseImmune Effector Cell Associated Neurotoxicity Syndrome (ICANS)SubgroupICD10G92.0MeSHNeurotoxicity SyndromesSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceAnakinraSupportive substanceAnakinraSupportive substanceAnakinraSupportive substanceAnakinraNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentionsupportiveRisks only studiesPublicationAuthorGazeau NDiseaseICANS, steroidrefraktärOriginRed Hutchinson Cancer Center, Seattle, Washington; Hematology Service, Centre Hospitalier Universitaire de Lille, Lille, FranceProtokolle in Überarbeitung 1 protocol foundAnakinra 100, Immune Effector Cell Associated Neurotoxicity Syndrome (PID3252 V1.0)
